Gilead news in 2026: 18 dated events
The latest Gilead event on this page is dated Oct 19, 2026. ad-hoc-news.de reported: Gilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion gradually.
Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.- Dated events
- 19
- Last 90 days
- 7
- Latest
- Oct 19, 2026
Source: Autobound Signal API · 68 signals tracked for Gilead · updated
News · latest 10
Latest Gilead news
Showing 10 of 19 dated events. The Signal API returns all of them.
Get them with one API call- Gilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion graduallyGilead reported positive Phase 2 clinical trial results for its investigational oral emvistegrast treatment for ulcerative colitis and plans to launch a Phase 3 study in 2027.
- Gilead Sciences stock reports growth at EUR 133.42, plus 0.02 percentGilead Sciences is developing oral treatments for mosquito-borne flaviviruses, supported by a new federal grant.
- Gilead opens new building on existing Foster City campusGilead Sciences unveiled a new 182,000 square-foot building on its existing campus in Foster City, which will house oncology and scientific research.
- Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Gilead Sciences is developing Yeztugo, a once-weekly oral HIV pre-exposure prophylaxis (PrEP) with a PDUFA target date of Feb. 2.
- FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsGilead Sciences launched its new once-daily HIV pill, Bixlenvo, after receiving approval from the U.S. Food and Drug Administration.
- Gilead's Second-Quarter Revenue Rises 8%, Exceeding Wall Street ForecastsGilead Sciences reported an adjusted loss per share of $6.75 for the second quarter, better than the analyst consensus expectation of a $7.24 loss.
- Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?Gilead Sciences received FDA approval for the label expansion of its breast cancer drug Trodelvy for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).
Showing 10 of 19 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Gilead with the Signal API
One POST /v1/companies/enrich call with gilead.com returns Gilead news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about Gilead news
What is the latest news on Gilead?
What is going on with Gilead?
Is Gilead laying off employees?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .